NY-INVESTABLE-UNIVERSE
22.9.2021 10:17:14 CEST | Business Wire | Press release
The real assets news site Investable Universe announces the launch of Polar Futures , a media series that examines the eight-nation Arctic region’s growing geopolitical importance and its potential for attracting hundreds of billions of dollars in direct investment to develop the region and its bounty of natural resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005180/en/
Institutional investors, pension funds and other investors are eyeing the potential of developing infrastructure, shipping, logistics, telecommunications, mining, aquaculture and marine resources and of incubating technologies that aid the transition to renewable energy.
Additionally, new trans-Arctic shipping lanes made more accessible by climate change will focus competing political and military interests on the polar zone.
Nuanced insights from pivotal figures
Against this fluid strategic backdrop, the weekly newsletter and podcast series, curated by editor-in-chief Rebecca Engmann Darst, will feature interviews with pivotal figures in the Arctic discourse, including:
- Greenlandic Minister of Foreign Affairs, Trade, Business and Climate Pele Broberg, on Greenland’s political atmosphere and the new government’s priorities for independence, social welfare and environmental protection
- Ambassador Einar Gunnarsson, who was Chair of the Senior Arctic Officials during Iceland’s chairmanship of the Arctic Council from 2019 to 2021, on Iceland’s role on the council and its recent transition of leadership to Russia
- Leslie Canavera, CEO of PolArctic LLC , an Alaska Native-owned small business, and Chair of the Arctic Economic Council Blue Economy Working Group, on the challenges and opportunities for AI models to support Arctic business and environmental sustainability
- Mac McHale, CRO of Alaskan telecommunications developer Quintillion and a 30-year veteran of broadband development, on the obstacles and potential of the U.S. Arctic telecom infrastructure buildout and how the region offers a test case not only for rugged Earth environments but also for space
- Anne Kirstine Hermann, a Danish journalist and the author of the new book Imperiets Børn (Children of the Empire) , on the legacy of Denmark’s compulsory integration of Greenland in the 1950s, the role of the United Nations and how these complex historical and cultural relationships might affect current and future Arctic development.
The series also will include insights about the roles of Canada, Finland, Norway, Russia and Sweden in the rapidly evolving Arctic zone.
Subscribers will gain exclusive access to nuanced transnational views of the polar investment and geopolitical landscape through a weekly newsletter and podcast interviews with guests from across the diplomatic, media and entrepreneurial spectrum.
Will globalization and climate change spur great-power rivalry in the Arctic?
Noting that research from the Council on Foreign Relations examined the Arctic as a potential site for “the return of great-power rivalry”[1] amid the challenges of globalization and climate change, Darst believes that the Arctic North will be the nexus of a number of conflicts and opportunities in the twenty-first century.
“The polar region’s strategic value is hard to overstate. It holds vast natural and mineral resources and is developing new and high-tech industries in parallel to those riches. Yet in the region, there’s also an intricate tapestry of historical and cultural factors that are rarely discussed on a global level. We will delve unflinchingly into all of them in the newsletter and podcast,” says Darst.
Subscribe to the Polar Futures newsletter and podcast bundle at www.investableuniverse.com/polarfutures .
About Investable Universe
Trofast Media’s Investable Universe provides leading edge insights into investment in real assets, the global “market of things” that spans traditional investments and emerging technologies on earth and in space.
Learn more at InvestableUniverse.com .
[1] https://www.cfr.org/in-brief/whats-stake-rising-competition-arctic
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
